Veterans Rx-Only Plan Would Reduce Price Negotiating Power, VA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
VA opposes the bill because it could lead to an increase in the amount and price of pharmaceuticals purchased. The department would prefer to be responsible for all the health care needs of veterans, Deputy Secretary Mansfield says during Senate hearing.
You may also be interested in...
Medicare Rx May Have Little Effect On VA Health System, Agency Says
Department of Veterans Affairs expects an actuary report on the effect of the Medicare Rx program in about eight weeks, official tells a House Veterans’ Affairs/Health Subcommittee hearing March 30. The hearing reopens debate on a drug-only health benefit for veterans.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.